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Schizophrenia and human leukocyte antigen (HLA) matching between couples or between mothers and offspring have
independently been associated with prenatal/obstetric complications, including preeclampsia and low birth weight. Here,
we report the results of a family-based candidate-gene study that brings together these two disparate lines of research
by assessing maternal-fetal genotype matching at HLA-A, -B, and -DRB1 as a risk factor of schizophrenia. We used a
conditional-likelihoodmodeling approach with a sample of 274 families that had at least one offspringwith schizophrenia
or a related spectrum disorder. A statistically signiﬁcant HLA-B maternal-fetal genotype–matching effect on schizophrenia
was demonstrated for female offspring ( ; parameter estimate 1.7 [95% conﬁdence interval 1.22–2.49]). BecausePp .01
the matching effect could be associated with pregnancy complications rather than with schizophrenia per se, these
ﬁndings are consistent with the neurodevelopmental hypothesis of schizophrenia and with accumulating evidence that
the prenatal period is involved in the origins of this disease. Our approach demonstrates how genetic markers can be
used to characterize the biology of prenatal risk factors of schizophrenia.
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Schizophrenia is a major public health challenge because
of its severity and prevalence. Several lines of converging
evidence support the consensus that schizophrenia is a
complex disorder with both genetic and environmental
causes.1 Yet, the speciﬁc genetic and environmental pro-
cesses that may combine to cause the disease have re-
mained difﬁcult to characterize. In a recent meta-analysis
of 12 twin studies that used a multigroup twin model,1
evidence emerged of both a substantial additive genetic
effect on schizophrenia (estimate of heritability 81% [95%
CI 73%–90%]) and a common or shared environmental
effect (estimate of heritability 11% [95% CI 3%–19%]).
Although the intrauterine environments of twin pairs are
not identical, they aremore similar than are environments
in later life; hence, the authors concluded that the pres-
ence of signiﬁcant common-environment effects on risk
of schizophrenia would most likely occur very early in
life. This prediction is consistent with a neurodevelop-
mental etiology of schizophrenia2,3 and with the body of
research on early risk factors of schizophrenia.4,5
Several reviews6,7 and a recent meta-analysis5 support the
involvement of pregnancy complications—such as bleed-
ing, diabetes, rhesus (Rh) incompatibility, preeclampsia, ab-
normal fetal growth and development, and delivery com-
plications—as risk factors of schizophrenia. Furthermore,
a recent study found that obstetric complications tended
to cluster within families with schizophrenia, especially
in multiply affected families,8 suggesting that the prenatal
complications that increase susceptibility to schizophre-
nia may themselves have a genetic origin.9 One clear ex-
ample of this is Rh incompatibility, since epidemiologic
and genetic analyses have found evidence that the RHD
locus (MIM 111680) is a risk factor of schizophrenia when
maternal-fetal genotype (MFG) combinations produce Rh
incompatibility.5,10–12
Rh incompatibility is an example of a maternal recog-
nition of, or sensitization to, fetal cells—in this case, spe-
ciﬁcally to fetal red blood cells carrying an antigen of pa-
ternal origin that maternal red blood cells lack. Once
sensitization has occurred, thematernal response involves
the production of immunoglobulin G antibodies, which
cross the placenta and lyse fetal red blood cells, producing
hyperbilirubinemia and hypoxia in the fetus.13 Evidence
from other lines of research suggests that these conditions
can affect brain development in ways that increase the
risk of schizophrenia.14–16 There is some evidence that sus-
ceptibility to schizophrenia as a function of Rh incom-
patibility pertains only to male offspring.12
It is generally accepted that there is maternal recogni-
tion of paternally derived fetal human leukocyte antigens
(HLAs) during pregnancy, since maternal antibodies
against these fetal antigens have been detected.17Maternal
recognition, or sensitization, likely occurs when fetal nu-
cleated cells, which bear paternally derived HLAs that dif-
fer from thematernal HLAs, enter thematernal circulation
system during pregnancy or delivery. However, because
maternal antibodies to fetal antigens have been observed
in a signiﬁcant proportion of healthy pregnancies, there is
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some belief that maternal sensitization may be beneﬁcial
for implantation and maintenance of pregnancy and that
lack of maternal sensitization may lead to adverse repro-
ductive outcomes.17 This line of reasoning has given rise
to a number of empirical studies evaluating the strength
of the relationship between HLA matching and reproduc-
tive outcomes. Although results are inconsistent in the
literature, there is some empirical evidence that HLA
matching between couples or betweenmother and fetus—
that is, situations in which maternal sensitization would
not occur—increases the risk of fetal loss,18–21 preeclamp-
sia,22–25 low birth weight,26–29 newborn encephalopathy,
and seizures.30 The underlying biologicalmechanism(s) for
poor reproductive outcomes are not yet known; however,
an immunological-intolerance hypothesis posits that HLA
similarity between mother and fetus fails to stimulate an
adequate maternal immune response that is necessary for
proper implantation and maintenance of pregnancy.20
The potential relevance of HLA matching to neurode-
velopmental disorders has been recognized. Stubbs et al.31
hypothesized that parents of children with autism would
be more likely to share HLAs than would parents of un-
affected controls, in part because of increased rates of pree-
clampsia and spontaneous abortions in mothers of chil-
dren with autism. The investigators found that parents of
children with autism were signiﬁcantly more likely to
share at least one HLA-A, -B, or -C antigen in common,
compared with parents of unaffected children.
Because risk of schizophrenia is associated with prena-
tal/obstetric complications, including preeclampsia and
low birth weight, and because maternal-fetal HLA match-
ing has been associated with these complications andwith
at least one other neurodevelopmental disorder, we hy-
pothesized that maternal-fetal HLA matching may be a
risk factor of schizophrenia. In this article, we examine
the role of MFG matching at HLA-A (MIM 142800), -B
(MIM 142830), and -DRB1 (MIM 142860) loci as a risk
factor of schizophrenia.
Independent nuclear families in which DNA was avail-
able from at least one parent and one offspring affected
with schizophrenia, schizoaffective psychosis disorder, or
schizophrenia spectrum disorder (i.e., schizoid, schizoty-
pal, and paranoid personality disorders; schizophreni-
form, delusional, and brief psychotic disorder; and psy-
chosis not otherwise speciﬁed) were selected for the
current study from a larger well-described and character-
ized Finnish schizophrenia sample.32–35 Probands in the
larger study, born between 1940 and 1976, were identiﬁed
through national health and population registers, and
their ﬁrst-degree relatives were recruited with permission
from the proband. Two psychiatrists or psychiatric resi-
dents made independent DSM-IV36 best-estimate lifetime
diagnoses for probands and their relatives, using all avail-
able inpatient and outpatient records. The research was
approved by the Ministry of Social Affairs and Health in
Finland and by the appropriate institutional review
boards, and subjects provided informed consent.
DNA was extracted from blood in accordance with a
standard procedure.37 HLA genotyping was performed by
an HLA clinical diagnostic and reference laboratory with
high inter- and intrasite reliability for DNA-based typing
of class I38 and class II39 genes. The quality and quantity
of the DNA was assessed by optical density and agarose-
gel checks. We genotyped individuals, blind to their di-
agnostic status, for HLA-A, -B, and -DRB1 antigens by PCR
ampliﬁcation followed by hybridization with sequence-
speciﬁc oligonucleotide probes, using Quick-Type HLA
typing kits in accordance with the manufacturer’s pro-
tocol (Tepnel Lifecodes). A total of 30 A-locus, 47 B-locus,
and 31 DRB1-locus probes were used to identify all World
Health Organization (WHO)–designated HLA-A, -B, and
-DRB1 alleles.40 The primers and probes used in the assay
were validated before use, for sensitivity and speciﬁcity,
on an HLA reference panel of DNA. With each batch of
unknown samples, control samples of known genotype
were evaluated to ensure accuracy. Negative controls (no
DNA) were included in each assay, to monitor for PCR-
amplicon contamination. After probe hybridization,
membranes were scanned using Quick-Type HLA Scan-
ning and Analysis software, and the assignment of the
HLA typing was based on the reaction pattern, compared
with patterns associated with published HLA gene se-
quences. The genotyping failure rate was ∼5% and was
primarily due to insufﬁcient quantities of DNA.
Individuals observed to have a single allele were treated
as homozygous for that allele. Genotype error checking
was performed using the mistyping option of Mendel
v6.0,41,42 which ﬂags genotypes requiring unlikely double
recombination, as well as Mendelian transmission errors.
A total of 13 individuals in 10 families with genotyping
errors were excluded from the analyses. The per-locus ge-
notyping error rate was 0.09%, 0.09%, and 0.9% for HLA-
A, -B, and -DRB1, respectively. There was no signiﬁcant
evidence of violation of Hardy-Weinberg equilibrium at
HLA-A ( ), -B ( ), or -DRB1 ( ) amongPp .28 Pp .21 Pp .08
the founder alleles when we used the Fisher’s exact test
implemented in Mendel v6.0.42
The current study sample is composed of 274 nuclear
families with 484 affected offspring ( , 70, and 42np 372
who received diagnoses of schizophrenia, schizoaffective
psychosis disorder, and schizophrenia spectrum disorder,
respectively). Sample sizes vary slightly byHLA locus, with
genotypes available for both parents in 118 families for
HLA-B and -DRB1 and in 117 families for HLA-A; in 115,
114, and 113 families for HLA-A, -DRB1, and -B, respec-
tively, when the father’s genotype is missing; and in 41,
40, and 39 families for HLA-B, -DRB1, and -A, respectively,
when the mother’s genotype is missing. The majority
(90%) of missing parental genotypes were due to lack of
availability of a DNA sample, and the remainder (15
individuals per locus) were due to genotyping difﬁculties.
All affected offspring with genotype data were included
in the analyses. When available, genotype data for unaf-
fected siblings were included, for the inference of parental
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genotypes when one parent’s genotype was missing. The
number of affected offspring per nuclear family ranged
from one to six; 60% of families had two or more affected
offspring, and 60% of affected offspring were male.
We ﬁrst conducted tests of NPL separately for HLA-A,
-B, and -DRB1, using Mendel v6.042 to determine whether
additional parameters for high-risk allelic effects should
be included in the models examining the role of MFG
matching. Single-point linkage analyses did not yield
strong signiﬁcant evidence of linkage in the families (ad-
ditive pairs NPL statistic for HLA-A , -B ,Pp .09 Pp .11
and -DRB1 ). Alternative NPL statistics (recessivePp .18
blocks, additive all, and dominant blocks) resulted in
equivalent or larger P values. Given the weakly signiﬁcant
linkage ﬁndings, particularly for HLA-A and -B, we next
tested for association. Multiallelic transmission/disequi-
librium tests did not yield signiﬁcant evidence of an as-
sociation with a speciﬁc HLA-A, -B, or -DRB1 allele that
could be acting through the affected offspring’s genotype
to increase susceptibility to schizophrenia ( ,Pp .83 Pp
, and , respectively). Repeating these analyses.48 Pp .21
by grouping together alleles with similar antigen speciﬁc-
ity (according to theWHO assignments40) did not produce
substantively different results. Because these analyses did
not provide evidence of the role of a high-risk allele, sub-
sequent analyses focused only on investigating whether
matching MFG combinations would increase risk of
schizophrenia.
To test hypotheses of MFG matching at these loci, the
multiple-sibling extension of the MFG test43 was modiﬁed
to handle multiallelic loci and missing parental geno-
types.44 This likelihood approach evaluates the distribu-
tion of parental and affected-offspring genotypes condi-
tioned on the offspring’s affection status and ﬁts the
likelihood , where Gi1 and Gi0
N Pr (G , G , G , G F D )i1 i0 im if i1ip1
are genotypes for the ni affected offspring and mi unaf-
fected offspring, respectively, in family ,…,N; Gim andip 1
Gif are genotypes for the mother and father, respectively;
and D is affection status. Phenotypes of the unaffected
offspring are not used in the likelihood calculation. With
the use of the Bayes theorem and the assumption that
siblings’ phenotypes are independent conditional on the
genotypes, this likelihood can be parameterized in terms
of penetrance functions and population mating-type
frequencies.43,45 We adopt a log-linear model for the pen-
etrances
Pr (D F G , G , G , G ) pi1 i1 i0 im if
I(MFG match and male) IMFG match and female( )m m m0 1 2
where I(.) is the indicator function. The parameter m0 is
the baseline risk, which ultimately cancels out the likeli-
hood. The parameters m1 and m2 represent relative risks due
to MFG matching when a matched affected offspring is
male or female, respectively, compared with a non-
matched affected offspring. The parameters m0, m1, and m2
are all positive. No assumption of Hardy-Weinberg equi-
librium is necessary. We included data from families with
incomplete parental genotypes in the likelihood calcula-
tion, by assuming that the genotypes are missing at ran-
dom and summing over all possible genotypes for the
parent.44
HLA loci are highly polymorphic. However, it is well
known from organ transplantation work that there are
subsets of alleles with similar antigen speciﬁcity, meaning
that they recognize and produce an immune response to
the same antigens. Because the immune hypothesis is
based on the idea of maternal sensitization, or lack
thereof, HLA-A, -B, and -DRB1 alleles with similar antigen
speciﬁcity were grouped together according to the WHO
assignments,40 for analyses to test hypotheses about the
effect of MFG matching on susceptibility to schizophre-
nia. The WHO grouping preserves the biological hypoth-
esis of maternal immunological intolerance and reduces
the number of “alleles” in the analyses.
Consistent with previous research reported elsewhere,46
we further hypothesized thatMFGmatching increases risk
of schizophrenia through a general allele-matching phe-
nomenon rather than through speciﬁc allele combina-
tions. Hence, we deﬁne parental mating types in the
model using the parental allele identity-by-state (IBS)
status under the assumption that the parental mating is
symmetric with regard to genotypes.46 For example, con-
sider a locus with six alleles, numbered 1–6. In the IBS
schema, families withmaternal genotype 1/3 and paternal
genotype 3/4 are in the same mating type as are families
with maternal genotype 2/4 and paternal genotype 4/5.
In each case, both parents are heterozygous; . TheIBSp 1
IBS schema has the additional attractive feature of reduc-
ing the number of mating types, which are considered
nuisance parameters, to be estimated.
For each locus, MFG matching was deﬁned in terms of
allele matching between the mother and offspring. Spe-
ciﬁcally, mother and offspring match if the offspring’s al-
leles are identical to the maternal alleles (e.g., mother 1/1
and offspring 1/1 or mother 1/2 and offspring 1/2) or if
the offspring’s alleles are a subset of the maternal alleles
(e.g., mother 3/4 and offspring 3/3). In each of these cases,
the antigens produced by the offspring’s alleles would not
be perceived by the mother as different from her own
during pregnancy, and maternal sensitization would not
occur.
We evaluate the role of MFG matching by placing dif-
ferent constraints on the relative risk parameters. Under
a null hypothesis—that MFG matching does not increase
susceptibility to schizophrenia—one would expect that
the distribution of parent and affected-offspring geno-
types would simply be based on the allele frequencies in
the population. The null model is evaluated by setting m1
and m2 to the null value of 1, whereas placing no con-
straints on m1 and m2 allows the MFG-matching risk to be
estimated separately for male and female offspring.
The maximum-likelihood estimates of the MFG-match-
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Table 1. Model Comparisons and Estimates of Relative
Risks of Schizophrenia Due to HLA-B MFG Matching
Model (95% CI)amˆ1 (95% CI)
bmˆ2
Log
Likelihood
0 p1 p1 1,018.17
1 1.11 (0.76–1.61) 1.74 (1.22–2.49) 1,013.63
2 p1 1.69 (1.20–2.38) 1,013.79
a Relative risk for sons who match at HLA-B with their mother.
b Relative risk for daughters who match at HLA-B with their mother.
ing parameters and the mating-type parameters were ob-
tained by solving score equations of the log likelihood,
and the SEs of the estimates were derived through the
observed information matrix.47 Hypothesis testing was
performed by a likelihood-ratio test whose statistic follows
asymptotically a x2 distribution with degrees of freedom
equal to the difference in the number of parameters es-
timated in nested models.
We tested the primary hypothesis of an HLA-A, -B, or
-DRB1 MFG-matching effect for males and females, by
comparing the model in which m1 and m2 are estimated
with a model in which . There was no signif-m p m p 11 2
icant evidence of an HLA-A ( , 2 df; ) or2x p 2.29 Pp .32
-DRB1 ( , 2 df; ) MFG-matching effect on2x p 3.34 Pp .19
schizophrenia. In contrast, this model comparison yielded
signiﬁcant evidence of an HLA-B MFG-matching effect on
schizophrenia ( , 2 df; ) (see table 1 for com-2x p 9.1 Pp .01
parison of model 0 with model 1), with parameter esti-
mates of (95% CI 0.76–1.6) and (95%ˆ ˆm p 1.1 m p 1.741 2
CI 1.22–2.49). Inspection of m1 and m2 parameter estimates
and their 95% CIs reveals that HLA-B MFG matching pro-
duces a higher risk of schizophrenia for female offspring
than for male offspring (table 1). We note that, in this
analysis, there were 185 families that could be assigned
to a speciﬁc mating type. Of those, 61 families were in-
formative for MFG matching and yielded 72 instances (35
females and 37 males) of MFG matching, compared with
37 instances (12 females and 25 males) of mismatching
between mothers and their affected offspring. The rate of
matching between affected daughters and their mothers
was higher than that between affected sons and their
mothers (74.5% and 59.7%, respectively), which is con-
sistent with the estimates of the matching parameters.
Although this comparison does not take into account the
effects of dependencies among siblings and missing pa-
rental genotype data (whereas the statistical analysis
does), it provides an intuitive feel for the increased fre-
quency of MFG matching at the HLA-B locus among af-
fected female offspring.
Because the coverage on m1 includes the null value of 1,
we next examined whether the effect was limited to fe-
males by comparing the model where m1 and m2 are un-
constrained (which allows males and females to be at dif-
ferent risk) with the model where (model 1 andm p 11
model 2, respectively, in table 1). We found that the un-
constrained model did not ﬁt signiﬁcantly better than the
model with ( , 1 df; ), which in-2m p 1 x p 0.32 Pp .571
dicates that, in this sample, only females are signiﬁcantly
affected by HLA-B MFG matching.
This article provides evidence that the HLA-B locus in-
creases schizophrenia risk for female offspring through an
MFG-incompatibility mechanism, in which risk is in-
creased when mothers and their daughters match for al-
leles at that locus. Further studies are needed to elucidate
the mechanism through which HLA-B matching increases
risk of schizophrenia. However, because HLA matching
has been found in some studies to increase the risk of
prenatal complications, the presence of an HLA-B MFG-
matching effect suggests that susceptibility to schizophre-
nia may be increased by an adverse prenatal environment,
because the matching effect could be associatedwith preg-
nancy complications rather than with schizophrenia per
se. These ﬁndings are consistent with the neurodevelop-
mental hypothesis of schizophrenia and with evidence
that the prenatal period is involved in the origins of this
disease. Furthermore, our results suggest that females are
more vulnerable to the effects of HLA-B MFG matching
on schizophrenia than are males. Although the explana-
tion for this differential sex phenomenon is not known,
a recent study demonstrated that, with preeclampsia (a
condition that has been associated with HLA-B matching)
with preterm delivery, female fetuses were more likely to
survive than were male fetuses.48 Thus, the effects of pree-
clampsia on schizophrenia may be more likely to be ob-
served among females because fewer males are likely to
survive the effects of preeclampsia.
We note that the estimates presented in this article may
be underestimates and that the true effects may be larger.
An assumption of the MFG test is that the probability of
an affected individual surviving to clinical detection does
not depend on the HLA genotypes of the parents and
offspring,49 and this assumption may be violated when
loci potentially reducing fetal viability are assessed, as in
the case of HLA loci. The effect of this violation would be
a reduction in the number of mother-offspring matches
in the sample, which would underestimate the true MFG-
matching effect. Analyses that incorporate genotype data
on phenotype-unknown siblings would enable fetal via-
bility to be estimated and would lead to a more accurate
estimate of the MFG-matching effect.45
Until recently, the investigation of prenatal risk factors
has been based on data extracted from medical records.
However, growing evidence that prenatal risk factors of
schizophreniamay, in fact, have a genetic originmotivates
the use of a genetic approach to identify and further study
the effects of these risk factors. Identifying genes that con-
tribute to an adverse prenatal environment that increases
risk of schizophrenia may serve to (i) increase power to
detect schizophrenia susceptibility genes, (ii) foster re-
search into the study of how susceptibility genes and pre-
natal environment act separately and together to produce
schizophrenia, and (iii) produce tailored risk assessments
for individuals with personal or family histories of
schizophrenia.
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